Insta
Bharat Biotech's COVAXIN (Representative Image) (Pic Via BBIL Website)
Bharat Biotech said on Tuesday (29 December) that its vaccine candidate, Covaxin, will be effective in dealing with new strains of coronavirus.
Bharat Biotech Chairman and Managing Director Krishna Ella said the protein components of inactive Covaxin will take care of mutations.
His comments came amid growing concerns over new strains of coronavirus SARS-CoV-2, especially the variant that was detected recently in the UK.
Krishna Ella, who was delivering the ninth Dr Manohar V N Shirodkar Memorial Lecture organised by the Telangana Academy of Sciences, observed that that any virus is expected to have a lot of mutation.
Hyderabad-based Bharat Biotech is developing Covaxin in collaboration with the Indian Council of Medical Research (ICMR). It has completed phase 1 and 2 clinical trials. The phase 3 efficacy trials of Covaxin were in progress with 20,000 volunteers, Ella said.
The leading vaccine maker is also developing a single-dose nasal vaccine for Covid-19.
In his lecture on "Innovation in Public Health - Our Journey," Ella said there were 40,000 unknown viruses and 10,000 zoonotic viruses and there was a need to focus on neglected and unknown diseases that could become global pandemics in future.
"All neglected diseases start from developing countries. Americans and Europeans are scared of us because these neglected diseases can turn into pandemics," he said.
(This story has been published from a wire agency feed without modifications to the text. Only the headline has been changed.)
Support Swarajya's 50 Ground Reports Project & Sponsor A Story
Every general election Swarajya does a 50 ground reports project.
Aimed only at serious readers and those who appreciate the nuances of political undercurrents, the project provides a sense of India's electoral landscape. As you know, these reports are produced after considerable investment of travel, time and effort on the ground.
This time too we've kicked off the project in style and have covered over 30 constituencies already. If you're someone who appreciates such work and have enjoyed our coverage please consider sponsoring a ground report for just Rs 2999 to Rs 19,999 - it goes a long way in helping us produce more quality reportage.
You can also back this project by becoming a subscriber for as little as Rs 999 - so do click on this links and choose a plan that suits you and back us.
Click below to contribute.
Latest